PegBio Co

PegBio Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of PegBio Co (2565.HK) as of Nov 18, 2026 is -111.83. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -81.70 — a change of 36.88% (lower).

EV/EBITDA

-111.83

YoY

36.88%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of PegBio Co is 2025 -111.83 . EV/EBITDA (Enterprise Value to EBITDA) of PegBio Co was 2024 -81.70 . It decreases by 36.88% lower compared to the previous year.

The PegBio Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2022
-72.30 CNY
Jan 1, 2023
-82.01 CNY
Jan 1, 2024
-81.70 CNY
Jan 1, 2025
-111.83 CNY
The PegBio Co EV/EBITDA history
YEAREV/EBITDAYoY
-111.83+36.88%
-81.70-0.38%
-82.01+13.42%
-72.30—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

EV/EBITDA (Enterprise Value to EBITDA) of PegBio Co is -111.83 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of PegBio Co changed from -81.70 to -111.83, representing a 36.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) PegBio Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s PegBio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — PegBio Co

All Key Metrics — PegBio Co